Viz.ai, an artificial intelligence (AI)-powered imaging and care coordination company, has partnered with Us2.ai to integrate the latter’s echocardiogram viewing and measurement tools with its Viz Platform.
The integration is aimed at enhancing and expediting the care coordination for individuals with suspected heart disease as well as to reduce the time from admission to treatment.
According to Viz.ai, the collaboration with Singaporean start-up Us2.ai will strengthen its position in the cardiovascular sector.
Us2.ai’s patented automated clinical workflow solution is said to find optimal images, capture measurements of the heart’s structure and function, and then deliver an echo report to clinicians in less than two minutes.
The FDA-cleared and CE Marked tool identifies and evaluates 2D and Doppler echo pictures to obtain full cardiac data required for the diagnosis of heart disease and pulmonary hypertension.
Viz.ai CEO Chris Mansi said: “Echo is an essential tool in the delivery of cardiovascular care. We believe that no heart disease patient should have to wait for care when time is critical.
“The average time to complete an echo takes up to 60 minutes, plus additional reporting time. Using AI can dramatically reduce this time burden, as well as ensure a uniform standard of excellence in reporting.
“We are proud to partner with Us2.ai to enhance and complement our comprehensive AI platform, tailoring it to cardiovascular needs, so that cardiologists and care teams can provide optimal care to more patients most efficiently.”
Viz.ai said that the Viz Platform with Us2.ai’s technology will speed up access to echocardiography results for clinicians and enhances patient access to time-critical diagnostics in the acute and post-acute care stages.
Us2.ai business development head Seth Koeppel said: “Viz.ai is a natural partner for Us2.ai given the proven success of its care coordination platform and its vast network covering 200 million lives.
“With a national shortage of sonographers, the combination of our leading-edge applications will support hospitals and providers as well as patients. We look forward to bringing the power of our AI-enabled cardiovascular solution to more cardiac care teams and patients across the U.S.”
Last month, Us2.ai signed an agreement with Israeli health technology firm Aidoc to integrate its patented algorithm into the latter’s platform, aiOS.
